PERRIGO Co plc

Note 14

NOTE 14 -RESTRUCTURING CHARGES

We periodically take action to reduce redundant expenses and improve operating efficiencies. Restructuring activity includes severance, lease exit costs, asset impairments, and related consulting fees. The following reflects our restructuring activity (in millions):

The charges incurred during the three and six months ended June 29, 2024 were primarily associated with actions taken on Project Energize activities. The charges incurred during the three and six months ended July 1, 2023 were primarily associated with actions taken on our multi-year supply chain restructuring program initiative started in 2022, and HRA Pharma integration activities associated with employee separation, continuity and other benefit-related costs.

Note 14

Of the amount recorded during the three and six months ended June 29, 2024, $24.2 million and $39.7 million was related to our CSCI segment and $2.1 million and $18.6 million related to our CSCA segment, and $10.6 million and $23.0 million was related to our Unallocated segment. For all segments, amounts were due primarily to Project Energize. Of the amount recorded during the three and six months ended July 1, 2023, $4.6 million and $6.7 million was related to our CSCI segment, due primarily to supply chain restructuring, and HRA Pharma integration initiatives, and $1.1 million and $2.4 million was related to our CSCA segment, also due primarily to supply chain restructuring initiatives.

There were no other material restructuring programs for the periods presented. All charges are recorded in Restructuring expense on the Condensed Consolidated Statements of Operations. The remaining $43.8 million liability for employee severance benefits and consulting fees is expected to be mostly paid within the next year.